NEUP

NASDAQ 已收盘

Neuphoria Therapeutics

2.35 USD
▲+0.03+1.29%
盘后 2.60 0.00%
2026-11-20
市值
$12.72M
市盈率
—
EPS
-0.96
股息率
—
52 周区间
2.26 – 5.53
成交量
55.96K
Beta
—
目标价
—
52W 低 2.2652W 高 5.53
价格走势

公司简介

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 recept...